Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2/25/25 20:37 | 2/21/25 | MGTX | Health | BioPrd | Biological Products, (No Diag | Zeldin Robert K | NY | O | Chief Me | 3 | M.d | 0 | 0.00 | 0 | 70 | 105 | 137 | D | ||||||||||||||
2/25/25 20:35 | 2/21/25 | MGTX | Health | BioPrd | Biological Products, (No Diag | Wollin Robert J | NY | O | GC,SECRE | 3 | M.d | 0 | 0.00 | 0 | 35 | 31 | D | |||||||||||||||
2/25/25 20:34 | 2/21/25 | MGTX | Health | BioPrd | Biological Products, (No Diag | Naylor Stuart | NY | O | CHIEF DE | 3 | M.d | 0 | 0.00 | 0 | 111 | 22 | 623 | D | ||||||||||||||
2/25/25 20:32 | 2/21/25 | MGTX | Health | BioPrd | Biological Products, (No Diag | Giroux Richard | NY | O | CFO,COO | 4 | M.d | 151 | 0.6815 | 0 | 222 | 29 | 997 | D | ||||||||||||||
2/25/25 20:31 | 2/21/25 | MGTX | Health | BioPrd | Biological Products, (No Diag | Forbes Alexandria | NY | DO | P,CEO | 4 | M.dm | 305 | 1.15 | 0 | 265 | 22 | 1,456 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |